YDES
Breeze AcquisitionCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
FY2025 revenue increased 17% to approximately $596.8 thousand, year-end cash was approximately $6.0 million, and management outlined multiple 2026 diagnostics and ophthalmology milestones. [#PR-EARNINGS-2026-05-01]
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
2026 IND and FDA Q-Submission plans are execution milestones, not regulatory approvals or efficacy evidence.
Momentum
66
Value
46
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.20 · Bull $3.25 · Bear $1.50
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum66 · Δ7d -
Value46 · Δ7d +0.0
Sentiment46 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
66
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
46
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 66.3 / Value 46.4 / Sentiment 46.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$160.79M
Beta
-
Shares Out
70.83M
P/E (TTM) · Derived
-18.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.94
Rev YoY
-
EPS YoY
-116.0%
Gross Margin
-
Op Margin
-
Net Debt
-$6M
Current Ratio
0.02
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology